- Schizophrenia:
- Immediate release:
- Adult: Initially PO 25mg BD then increased daily in increments of 25-50mg divided BD/TDS to 300-400mg by day 4
- Can be further increased by 25-50mg BD at intervals ≥2 days
- Maintenance: 150-750mg/day
- Adult: Initially PO 25mg BD then increased daily in increments of 25-50mg divided BD/TDS to 300-400mg by day 4
- Immediate release:
-
-
- Children 13-17 years: PO 25mg BD *1/7, then 50mg BD *1/7, then increased by 100mg/day up to 200mg BD by day 5, then may be increased by 50-100mg/day PRN
- Maintenance: 400-800mg/day
- Max: 800mg/day
- Children 13-17 years: PO 25mg BD *1/7, then 50mg BD *1/7, then increased by 100mg/day up to 200mg BD by day 5, then may be increased by 50-100mg/day PRN
-
-
- Extended release:
- Adult: Initially PO 300mg nocte, then increased up to 300mg/day PRN
- Maintenance: 400-800mg/day
- Max: 800mg/day
- Adult: Initially PO 300mg nocte, then increased up to 300mg/day PRN
- Extended release:
-
-
- Children 13-17 years: Initially 50mg nocte*1, then 100mg *1, then increased by 100mg/day
- Maintenance: 400-800mg/day
- Max: 800mg/day
-
- Manic bipolar I disorder as monotherapy or as an adjunct to lithium or divalproex:
- Immediate release:
- Adults: Initially PO 50mg BD, then increased by 100mg/day up to 200mg BD by day 4, then may increase by 200mg/day PRN
- Maintenance: 200-400mg BD
- Max: 800mg/day
- Adults: Initially PO 50mg BD, then increased by 100mg/day up to 200mg BD by day 4, then may increase by 200mg/day PRN
- Immediate release:
-
-
- Children 10-17 years: 25mg BD *1, then 50mg BD *1, then increased by 100mg/day up to 200mg BD by day 5, then may increased by 50-100mg/day PRN
- Maintenance: 400-600mg/day divided BD/TDS
- Max: 600mg/day
-
-
- Extended release:
- Adults: Initially PO 300mg nocte *1, then 600mg *1, then may adjust by 200mg/day PRN
- Maintenance: 400-800mg/day
- Max: 800mg/day
- Adults: Initially PO 300mg nocte *1, then 600mg *1, then may adjust by 200mg/day PRN
- Extended release:
-
-
- Children 10-17 years: PO 50mg *1, then 100mg *1, then increased by 100mg/day
- Maintenance: 400-600mg OD
- Max: 600mg/day
- Children 10-17 years: PO 50mg *1, then 100mg *1, then increased by 100mg/day
-
- Acute depressive bipolar disorder:
- Immediate release: PO 50mg nocte *1, then 100mg *1, then 200mg *1, then 300mg *1
- Maintenance: 300mg
- Max: 600 mg/day
- Immediate release: PO 50mg nocte *1, then 100mg *1, then 200mg *1, then 300mg *1
-
- Extended release: PO 50mg nocte *1, then 100mg *1, then 200mg *1, then 300mg
- Maintenance: 300mg
- Max: 300mg/day
- Extended release: PO 50mg nocte *1, then 100mg *1, then 200mg *1, then 300mg
- Maintenance in bipolar I disorder as an adjunct to lithium or divalproex:
- Immediate release: PO 400-800mg/day divided BD
- Extended release: PO 400-800 mg/day in single dose
- Major depressive disorder as adjunct to antidepressants:
- Initially PO 50mg nocte *2/7 then may be increased to 150mg
- Maintenance: 150-300 mg/day
- Initially PO 50mg nocte *2/7 then may be increased to 150mg
- Alcohol dependence (Off-label):
- PO 25-50mg nocte
- Max 300mg
- Insomnia (Off-label):
- Initially 25mg/day nocte
- Initially 25mg/day nocte
- Treatment-resistant anxiety disorder (Off-label):
- Immediate release: Initially 25mg OD, then increased by 25-50mg/day
- Maintenance: 50-150mg/day
- Max: 300mg/day
- Immediate release: Initially 25mg OD, then increased by 25-50mg/day
-
- Extended release: Initially 50mg OD, then may be increased by 50mg/day
- Maintenance: 50-150mg/day
- Max: 300mg/day
- Extended release: Initially 50mg OD, then may be increased by 50mg/day
- Tablet:
- 50mg
- 100mg
- 150mg
- 200mg
- 300mg
Preferably to be taken in evening without food or with a light meal
2nd generation atypical antipsychotic
It is thought to reduce positive and negative symptoms of psychotic disorders via antagonism of multiple neurotransmitter receptors in brain, including dopamine D1 and D2, histamine H1, alpha1- and alpha2-adrenergic and serotonin types 1 and 2 (5-HT1A, 5-HT2)
- Somnolence
- Xerostomia
- Dizziness
- Orthostatic hypotension
- Increased BP (peds patients)
- Tachycardia
- Hypotension
- Constipation
- Weight gain
- Diarrhea (peds patients)
- Increased appetite
- Dyspepsia
- Tremor
- Dysarthria
- Dysphagia
- Extrapyramidal symptoms
- Blurred vision
- Anemia
- Rash
- Transiently elevated ALT/AST
- Abdominal pain
- Back pain
- Hyperprolactinemia
- Increased cholesterol
- Hypertriglyceridemia
- Asthenia
- Headache
- Fatigue
- Insomnia
- Irritability
- Nausea
- Vomiting
- Peripheral edema
- Fever
- URI symptoms
- Impaired body temperature regulation
- Anticholinergic effects
- Hypersensitivity to components
- Uncorrected electrolyte abnormalities
- Hypokalemia
- Hypomagnesemia
- Congenital long QT syndrome
- Arrhythmia history
- Bradycardia
- QT prolongation
- Abrupt withdrawal
WARNING
- May cause tardive dyskinesia (often irreversible)
- Not approved for dementia-related psychosis, there is an increased mortality risk in elderly dementia patients on conventional or atypical antipsychotics
- Increased suicidality risk in children, adolescents and young adults with major depressive or other psychiatric disorders
- Lurasidone
- Lefamulin
- Pimozide
- Thioridazine
Drug Status
| Availability | Prescription only |
| Pregnancy | Category C |
| Breastfeeding | Weigh risk vs benefit |
| Schedule | Controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Quti | 200mg | Tablet | 30’s | Lords Healthcare | Lords Healthcare |
| Quti | 150mg | Tablet | 30’s | Lords Healthcare | Lords Healthcare |
| Quti | 50mg | Tablet | 30’s | Lords Healthcare | Lords Healthcare |
| Qutipin | 50mg | Tablet | 30’s | Sun Pharma | Sun Pharma |
| Qutipin | 100mg | Tablet | 30’s | Sun Pharma | Sun Pharma |
| Qutipin | 200mg | Tablet | 30’s | Sun Pharma | Sun Pharma |
| Qutipin | 300mg | Tablet | 30’s | Sun Pharma | Sun Pharma |